Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host

HER2 is overexpressed in 20% of invasive breast cancers (BCs) and correlates with a more aggressive disease. Until the advent of targeted agents, HER2 was associated with worse outcomes. Rationally designed HER2-targeted agents have been developed and introduced into clinical practice for women with...

Full description

Bibliographic Details
Main Authors: Martina Di Modica, Elda Tagliabue, Tiziana Triulzi
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2017/7849108

Similar Items